Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance

NCT02017327 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT02017327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02017327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance
Lead sponsor
Laboratoires Thea
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2013
Completion date
July 31, 2016
Enrollment
379 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, primary open angle glaucoma